BRAF and melanoma: In patients with BRAFV600E-positive melanoma enrolled in large randomized phase III studies, treatment with BRAF kinase inhibitors such as vemurafenib and dabrafenib resulted in response rates of over 50–60% and progression-free survival (PFS) of 6–7 months.